Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2025 May;39(5):1046-1054.
doi: 10.1111/jdv.20385. Epub 2024 Nov 25.

Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO study

Cécilia Maillet  1   2 , Olivia Boccara  3 , Stéphanie Mallet  4 , Didier Bessis  5 , Christine Labrèze  6   7 , Sorilla Mary-Prey  6   7 , Laurent Guibaud  8 , Annouk Bisdorff  9 , Anne Dompmartin  10 , Juliette Mazereeuw-Hautier  11 , Christine Chiaverini  12 , Thomas Hubiche  12 , Bertille Bonniaud  13 , Caroline Degrugillier-Chopinet  14 , Anne-Claire Bursztejn  15 , Hélène Aubert  16 , Maella Severino  11 , Sophie Leducq  1   2   17 , Mathilde Tardieu  18 , Aline Joly  1   19 , Grégoire Boulouis  1   20 , Anne Le Touze  1   21 , Arnaud Paré  1   19 , Elsa Tavernier  17   22 , Annabel Maruani  1   2   17
Affiliations
Observational Study

Long-term effects of sirolimus treatment for slow-flow vascular malformations: Real-world evidence from the French observational multicentre SIROLO study

Cécilia Maillet et al. J Eur Acad Dermatol Venereol. 2025 May.

Abstract

Rationale: Sirolimus is a treatment for slow-flow vascular malformations (SFVMs). However, the long-term management remains challenging.

Objectives: The SIROLO study assessed the long-term effects and real-life management of oral sirolimus for SFVMs by investigating data from 15 French tertiary centres for vascular anomalies.

Methods: Participants were retrospectively included if they had a SFVM that was being/had been treated with sirolimus for at least 3 years in total. Data were collected on treatment goals when initiating sirolimus, investigator-reported efficacy, safety, dosages and treatment withdrawal.

Results: The cohort involved 67 patients with various SFVM entities (mean [±SD] age 19.6 ± 12.5 years, 35 children, 52.2%). We found a heterogeneity of predefined treatment goals, the most frequent being cessation of pain. The investigators considered that sirolimus had persistent efficacy for bleeding, ulceration and pain but only slight efficacy for reducing volume. It was reported to be well-tolerated, although serious adverse events (mainly infections and also two ovarian cysts) were reported in 6 patients (9.0%) and required definitive sirolimus discontinuation for one. Overall, 11 patients (16.4%) had at least one temporary withdrawal period, leading to symptom recurrence and sirolimus resumption at a mean of 6.4 ± 9.6 months. The mean sirolimus concentration was 6.4 ± 3.7 ng/mL during the first 6 months and decreased over time (mean concentration during the last 6 months: 4.2 ± 3.2 ng/mL), probably to target the minimal efficient dosage. Eight patients (11.9%) switched to alpelisib because of insufficient efficacy of sirolimus.

Conclusions: This real-life study gives answers to frequent questions patients and parents ask before sirolimus initiation for SFVMs, such as persistence of efficacy over time, long-term side effects and time to recurrence in case of withdrawal.

PubMed Disclaimer

References

REFERENCES

    1. Wassef M, Blei F, Adams DM, Alomari A, Baselga E, Berenstein A, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics. 2015;136(1):e203–e214.
    1. Keppler‐Noreuil KM, Rios JJ, Parker VE, Semple RK, Lindhurst MJ, Sapp JC, et al. PIK3CA‐related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation. Am J Med Genet A. 2015;167A(2):287–295.
    1. Martinez‐Lopez A, Blasco‐Morente G, Perez‐Lopez I, Herrera‐Garcia JD, Luque‐Valenzuela M, Sanchez‐Cano D, et al. CLOVES syndrome: review of a PIK3CA‐related overgrowth spectrum (PROS). Clin Genet. 2017;91(1):14–21.
    1. Ten Broek RW, Eijkelenboom A, van der Vleuten CJM, Kamping EJ, Kets M, Verhoeven BH, et al. Comprehensive molecular and clinicopathological analysis of vascular malformations: a study of 319 cases. Genes Chromosomes Cancer. 2019;58(8):541–550.
    1. Arleo TL, Swerdlin RF, Gill AE, Goudy SL, Meisel JA, Briones MA, et al. Baseline quality of life in pediatric patients with low‐flow vascular malformations. J Pediatr Hematol Oncol. 2023;45(7):e847–e856.

Publication types

LinkOut - more resources